The U.S. Food and Drug Administration (FDA) has issued a formal Warning Letter to Novo Nordisk Inc., one of the world’s largest pharmaceutical manufacturers, detailing serious and systemic violations in the company’s post-marketing adverse drug experience (ADE) reporting processes.
The violations, identified during an FDA inspection conducted between January 13 and February 7, 2025, involve failures to report critical safety information, including deaths, strokes, and suicides, within required timeframes for drugs including semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda).
The FDA emphasized that these are not isolated incidents but represent systemic failures in Novo Nordisk’s surveillance, receipt, evaluation, and reporting of adverse drug experiences.
Overview of Violations
The FDA’s Warning Letter (Reference #26-HFD-45-03-01, Case #717576) documents multiple critical failures that collectively represent what the Agency characterizes as “systemic failures” in Novo Nordisk’s safety monitoring infrastructure. The company failed to comply with Section 505(k) of the Federal Food, Drug, and Cosmetic Act and Title 21 CFR 314.80, regulations that establish mandatory timelines and procedures for reporting postmarketing adverse events to the FDA.
The inspection focused on four active ingredients: semaglutide, liraglutide, nedosiran sodium, and estradiol, though the FDA explicitly noted concerns about “the scope and impact of these violations on your entire product portfolio” (emphasis in original).
This means the FDA suspects similar problems may exist across all of Novo Nordisk’s marketed pharmaceutical products.
Overview of Violations
The FDA’s Warning Letter (Reference #26-HFD-45-03-01, Case #717576) documents multiple critical failures that collectively represent what the Agency characterizes as “systemic failures” in Novo Nordisk’s safety monitoring infrastructure. The company failed to comply with Section 505(k) of the Federal Food, Drug, and Cosmetic Act and Title 21 CFR 314.80, regulations that establish mandatory timelines and procedures for reporting postmarketing adverse events to the FDA.
The inspection focused on four active ingredients: semaglutide, liraglutide, nedosiran sodium, and estradiol, though the FDA explicitly noted concerns about “the scope and impact of these violations on your entire product portfolio” (emphasis in original).
This means the FDA suspects similar problems may exist across all of Novo Nordisk’s marketed pharmaceutical products.
Key Regulatory Violations
1. Failure to Report Serious, Unexpected Events Within 15-Day Requirement
The most critical violation centers on Novo Nordisk’s failure to report Serious and Unexpected ADEs to the FDA within the mandated 15-calendar-day window. The FDA identified multiple cases where the company rejected or cancelled reportable adverse events based on whether internal reviewers or patients deemed the events causally unrelated to the drug.
2. Inadequate Procedural Safeguards and Vendor Oversight
Novo Nordisk contracted with call center vendors to handle adverse event intake and initial processing. The company’s written procedures (Q014048 and Q040018) contained critical gaps that allowed significant safety information to be lost or delayed.
3. Failure to Investigate Serious Adverse Events
FDA regulations require applicants to “promptly investigate all ADEs that are the subject of postmarketing 15-day Alert reports” (21 CFR 314.80(c)(1)(ii)). Novo Nordisk’s procedure (Q0360683) stated that the company would not follow up with non-healthcare professional reporters unless explicit consent was obtained, a requirement not mandated by FDA regulations.
Medical Review Processing Delays
Novo Nordisk’s procedure (Q040018) specified that the most serious adverse reactions should be entered into medical review by calendar day 9 following the awareness date and completed by calendar day 10. However, cases routinely remained in “medical review” status far longer than specified, causing failures to meet the 15-day reporting deadline.
FDA’s Broader Concerns About Entire Product Portfolio
The FDA emphasized that while the inspection focused on a sample of Novo Nordisk’s products (semaglutide, liraglutide, nedosiran sodium, and estradiol), the nature and scope of violations raise concerns about the entire product portfolio. The agency stated:
Your explanations, when taken into consideration with the violations described above and your failure to adequately address your noncompliance, suggest systemic failures with your surveillance, receipt, evaluation, and reporting of ADEs to FDA. In addition, your failure to identify and assess the root cause(s) of deficiencies discussed in this letter raises concerns about your firm’s ability to monitor the safety of your products, including through oversight of vendors to whom you contract to fulfill any of your ADE responsibilities. While this inspection focused on NNI’s compliance with PADE regulations for a sample of NNI’s products…based on the nature of the inspection’s findings and your written response and correspondence, we have serious concerns about the scope and impact of these violations on your entire product portfolio.
This statement indicates the FDA believes similar problems may extend far beyond the inspected products.
Novo Nordisk’s Response and Proposed Corrective Actions
Novo Nordisk has submitted multiple responses to the FDA (dated March 3, April 11, May 2, June 6, July 11, September 19, October 31, 2025, and January 15, 2026). The company’s stated corrective and preventive actions (CAPAs) include:
- Procedural Revisions: Removing terminology creating ambiguity regarding causality and relatedness in adverse event definitions.
- Retrospective Reviews: Conducting comprehensive reviews of cases to ensure all valid cases were submitted to the FDA (completed as of February 6, 2025, for sampled products).
- Process Improvements: Implementing daily reviews of patient safety cases across workflow states.
- Vendor Transition: Planning a phased transition of safety case intake from contracted call center agents to dedicated, in-sourced patient safety agents who are healthcare professionals.
- Organizational Changes: Creating dedicated Vendor Management, Quality, and Training teams within the U.S. Patient Safety team.
- Contract Updates: Removing consent requirements from safety data exchange agreements (SDEAs) with vendors.
- Comprehensive Audit: Conducting a retrospective review of all closed pharmacovigilance-related deviations dating back to June 2017 (completed; final report received).
FDA’s Assessment of Novo Nordisk’s Response
Despite these stated actions, the FDA found the company’s responses inadequate. Specific deficiencies cited by the FDA include:
FDA’s Stated Concerns
- Lack of Detail: “You did not provide sufficient details for the Agency to determine whether your actions effectively resolved the existing issues and will prevent similar violations in the future”.
- Vendor Oversight Unclear: No specific information about how vendor management teams will operate, what their activities will be, or how they will ensure vendor compliance.
- Insourcing Plan Vague: No adequate description of how the “insourced” call center will operate or assurance that it will comply with PADE requirements.
- Root Cause Analysis Incomplete: Failed to provide details about the root cause of medical review delays or assessment of whether this issue affects other products.
- Verification Insufficient: Did not provide case numbers and dates submitted to FDA for all cases identified in deviation DV0166369.
The FDA concluded:
Your written response and subsequent correspondence are inadequate because you did not provide sufficient details for the Agency to determine whether your actions effectively resolved the existing issues and will prevent similar violations in the future.
Broader Industry Implications
This Warning Letter carries significant implications for the pharmaceutical industry, particularly:
1. Vendor Responsibility and Oversight
Companies cannot delegate safety reporting responsibility to contractors without maintaining robust oversight. Novo Nordisk’s failures underscore that applicants remain liable for vendor performance regardless of delegation. This Warning Letter will be cited as precedent to establish that companies must:
- Verify that vendors are actually performing duties as required.
- Audit vendor performance regularly.
- Implement corrective actions with evidence of effectiveness.
- Train vendors continuously on regulatory requirements.
2. Causality and Relatedness Determinations
Applicants cannot exclude adverse events from reporting based on internal assessments of causality or relatedness. The FDA will make those determinations; companies must report all events meeting the regulatory definition of ADE, regardless of perceived likelihood of drug causation.
3. Gap Between Written Procedures and Actual Practice
Having written procedures alone is insufficient. Companies must audit and verify that procedures are actually followed in practice. The gap between Novo Nordisk’s written procedures (which appeared reasonable) and actual practice (where cases were improperly rejected) was a central concern. This suggests the FDA will intensify its focus on procedure compliance verification.
4. Root Cause Analysis Requirements
The FDA expects companies to thoroughly analyze why violations occurred and to provide detailed evidence that corrective actions address root causes and prevent recurrence. Vague or generic explanations will not satisfy the Agency.
5. Effectiveness Verification
Closing deviations without confirming that corrective actions are effective and without providing comprehensive documentation to the FDA creates significant risk. Companies must demonstrate effectiveness through data, not just assertion.
Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN
The FDA has granted traditional approval to Novartis' Fabhalta (iptacopan) — the first complement inhibitor shown to significantly slow kidney function decline in adults with […]
LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C
The LIPFENDRA FDA approval makes Merck's enlicitide the first once-daily oral PCSK9 inhibitor cleared to lower LDL-C in adults with hypercholesterolemia, including HeFH. Phase 3 […]
GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline
GSK has completed its $10.6 billion acquisition of Nuvalent, Inc., gaining three targeted lung cancer therapies, including zidesamtinib and neladalkib, both currently under FDA review […]
Outlook and Future Regulatory Actions
Several scenarios are possible:
Favorable Scenario
Novo Nordisk provides a comprehensive response within 15 business days, demonstrating that corrective actions have been effectively implemented, vendor systems are now robust, and procedures have been updated and verified. The company conducts additional inspections internally and shares findings with the FDA. If credible, the FDA may close the matter with periodic compliance audits.
Escalation Scenario
If Novo Nordisk’s response continues to be vague, incomplete, or unconvincing, the FDA will likely:
- Schedule a follow-up inspection to verify corrective actions.
- Issue a Consent Decree requiring third-party oversight of safety operations.
- Pursue criminal prosecution for knowing violations.
- Consider product-specific regulatory actions.
Portfolio Inspection Scenario
The FDA may conduct broader inspections of Novo Nordisk’s entire postmarketing safety operation to determine the full scope of violations across all products. Such inspections could take many months and result in additional warnings or escalated enforcement.
Last Modified:
